Business
Senzo & Abingdon enter into strategic partnership
Senzo & Abingdon enter into strategic partnership.
About this update from Abingdon Health Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n \n Abingdon Health plc\n \n \n \n (\"Abingdon Health\" or \"the Company\")\n \n \n \n \n \n \n \n \n Senzo and Abingdon Health enter into strategic partnership\n \n \n \n \n Abingdon Health's CDMO service to support Senzo in leveraging its innovative, high-accuracy Amplified Lateral Flow (ALF) point-of-care diagnostics platform technology across multiple product opportunities\n \n \n \n \n \n \n Senzo Health Limited (London, UK) (\"Senzo\") and Abingdon Health plc (York, UK) (\"Abingdon Health\") announce the signing of a strategic partnership agreement.\n \n \n \n \n \n Under the terms of the partnership Abingdon Health will support Senzo by providing contract development and manufacturing (\"CDMO\") services to Senzo and its partners to enable them to develop and manufacture new rapid tests utilising Senzo's cutting-edge ALF platform.\n \n \n \n \n \n Senzo is a leading innovator in the rapid diagnostics testing market, with its revolutionary lateral flow technology delivering the same accuracy as laboratory-based PCR with results available within 10 minutes, at a fraction of the cost. Senzo Health's technology is initially being applied to the development of a Covid-19 antigen assay, a broader respiratory panel, and other infectious disease tests. However, there are a wide range of applications across clinical, animal health, food, plant pathogen and environmental testing that would benefit from strengths of Senzo's platform technology. This strategic partnership will allow Senzo's partners to accelerate product development through access to Abingdon Health's CDMO services.\n \n \n \n \n \n Abingdon Health is a leading lateral flow CDMO offering its services to an international customer base across a range of industry sectors. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from \"idea to commercial success\". All projects are managed through Abingdon Health's quality management system and its services include feasibility, optimisation, technical transfer, manufacturing, regulatory and commercial support. Its UK-based automated manufacturing operations are capable of producing tens of millions of lateral flow tests per annum.\n \n \n \n \n \n \n Jeremy Stackawitz, CEO of ...